STUDY OF HUMAN-IMMUNODEFICIENCY-VIRUS RESISTANCE TO 2'-3'-DIDEOXYINOSINE AND ZIDOVUDINE IN SEQUENTIAL ISOLATES FROM PEDIATRIC-PATIENTS ON LONG-TERM THERAPY

被引:19
作者
DIMITROV, DH
HOLLINGER, FB
BAKER, CJ
KLINE, MW
DOYLE, M
BREMER, JW
SHEARER, WT
机构
[1] BAYLOR COLL MED,DIV MOLEC VIROL,1 BAYLOR PLAZA,HOUSTON,TX 77030
[2] BAYLOR COLL MED,DEPT PEDIAT,INFECT DIS SECT,HOUSTON,TX 77030
[3] BAYLOR COLL MED,ALLERGY & IMMUNOL SECT,HOUSTON,TX 77030
[4] TEXAS CHILDRENS HOSP,HOUSTON,TX 77030
[5] VET ADM MED CTR,REG CTR AIDS & HIV INFECT,HOUSTON,TX 77211
[6] UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225
关键词
D O I
10.1093/infdis/167.4.818
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Resistance to zidovudine (3'-azido-3-deoxythymidine) and 2',3'-dideoxyinosine (ddl) has been reported for human immunodeficiency virus (HIV) isolates from adults, but little is known about these drugs in children. A new micrococulture assay was developed for evaluation of drug susceptibility using single-passage HIV isolates cocultured with peripheral blood mononuclear cells from healthy donors. HIV isolates from children treated with zidovudine or ddl were evaluated to define the emergence of resistance to these antiretroviral agents. Four patients were treated with ddl and 3 with zidovudine for > 1 5 months. There was a greater-than-or-equal-to 20-fold decrease in susceptibility to ddl for sequential isolates of HIV recovered from 4 patients treated with ddl for 22-31 months and a 4- to 10-fold decrease in susceptibility to zidovudine in 3 patients. HIV isolates from 3 patients treated with ddl or zidovudine alone showed a minor amount of cross-resistance to the other antiretroviral agent. Results indicate the importance of monitoring antiretroviral drug susceptibility of HIV isolates when assessing clinical deterioration in children treated for > 1 year.
引用
收藏
页码:818 / 823
页数:6
相关论文
共 41 条
[1]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[2]   INHIBITION BY AZT OF HIV-1 REPLICATION IN ACUTELY INFECTED U-937 CELLS [J].
BOULERICE, F ;
WAINBERG, MA .
JOURNAL OF LEUKOCYTE BIOLOGY, 1990, 47 (06) :498-505
[3]  
BOZZETTE S, 1990, AM J MED S5B, V88, P24
[4]   HIV-1 SENSITIVITY TO ZIDOVUDINE - A CONSENSUS CULTURE TECHNIQUE VALIDATED BY GENOTYPIC ANALYSIS OF THE REVERSE-TRANSCRIPTASE [J].
BRUNVEZINET, F ;
INGRAND, D ;
DEFORGES, L ;
GOCHI, K ;
FERCHAL, F ;
SCHMITT, MP ;
JUNG, M ;
MASQUELIER, B ;
AUBERT, J ;
BUFFETJANVRESSE, C ;
FLEURY, H .
JOURNAL OF VIROLOGICAL METHODS, 1992, 37 (02) :177-188
[5]   HIV-1 SENSITIVITY TO ZIDOVUDINE - NEED FOR PHENOTYPIC ANALYSIS [J].
BRUNVEZINET, F ;
FLEURY, H .
RESEARCH IN VIROLOGY, 1992, 143 (02) :132-133
[6]   DIDEOXYINOSINE IN CHILDREN WITH SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BUTLER, KM ;
HUSSON, RN ;
BALIS, FM ;
BROUWERS, P ;
EDDY, J ;
ELAMIN, D ;
GRESS, J ;
HAWKINS, M ;
JAROSINSKI, P ;
MOSS, H ;
POPLACK, D ;
SANTACROCE, S ;
VENZON, D ;
WIENER, L ;
WOLTERS, P ;
PIZZO, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (03) :137-144
[7]   DEVELOPMENT OF A SENSITIVE QUANTITATIVE FOCAL ASSAY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTIVITY [J].
CHESEBRO, B ;
WEHRLY, K .
JOURNAL OF VIROLOGY, 1988, 62 (10) :3779-3788
[8]   ANTIRETROVIRAL THERAPY - STRATEGIES BEYOND SINGLE-AGENT REVERSE-TRANSCRIPTASE INHIBITION [J].
CONNOLLY, KJ ;
HAMMER, SM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :509-520
[9]   ANTIRETROVIRAL THERAPY - REVERSE-TRANSCRIPTASE INHIBITION [J].
CONNOLLY, KJ ;
HAMMER, SM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (02) :245-254
[10]   MINIMAL REQUIREMENTS FOR THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 V3 DOMAIN TO SUPPORT THE SYNCYTIUM-INDUCING PHENOTYPE - ANALYSIS BY SINGLE AMINO-ACID SUBSTITUTION [J].
DEJONG, JJ ;
DERONDE, A ;
KEULEN, W ;
TERSMETTE, M ;
GOUDSMIT, J .
JOURNAL OF VIROLOGY, 1992, 66 (11) :6777-6780